Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EndoTex Interventional Systems Inc.

This article was originally published in Start Up

Executive Summary

EndoTex has chosen to focus on two of the largest non-coronary applications among vascular disorders, AAAs and carotid artery disease.

You may also be interested in...



Interview with Fred Khosravi

In Vivo interviews device entrepreneur Fred Khosravi about his secrets for success in medical device company creation. Khosravi was part of the ACS organization that eventually became Guidant, where he was on the leading edge of the coronary stent revolution. That experience provided Khosravi with a broad background in interventional cardiology devices that was useful in starting his first company, carotid stent company EndoTex Interventional Systems (which was acquired by Boston Scientific) and several other successful companies.

AAA and Vascular Device Start-Ups

The first generation less-invasive devices for abdominal aortic aneurysm (AAA) surgery haven't yet been approved and the next generation is already here.

Recent eMDR Change By FDA Asks Adverse Event Reporters About Third-Party Servicers

The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel